These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11222571)

  • 1. Detection of glycopeptide resistance in Staphylococcus aureus.
    Walsh TR; Howe RA; Wootton M; Bennett PM; MacGowan AP
    J Antimicrob Chemother; 2001 Mar; 47(3):357-8. PubMed ID: 11222571
    [No Abstract]   [Full Text] [Related]  

  • 2. Strain-specific expression levels of pbp4 exist in isolates of glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3598-9. PubMed ID: 16048995
    [No Abstract]   [Full Text] [Related]  

  • 3. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of spontaneous resistance to glycopeptide antibiotics in staphylococcal populations.
    Biavasco F; Montanari MP; Facinelli B; Varaldo PE
    J Chemother; 1989 Jul; 1(4 Suppl):389-90. PubMed ID: 16312453
    [No Abstract]   [Full Text] [Related]  

  • 5. Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50.
    Utaida S; Pfeltz RF; Jayaswal RK; Wilkinson BJ
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1541-5. PubMed ID: 16569879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of staphylococci to paldimycin, and emergence of resistance, in vitro.
    Chandrasekar PH; Sluchak JA
    J Antimicrob Chemother; 1989 Nov; 24(5):821-4. PubMed ID: 2600003
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.
    Diederen BM; van Duijn I; Willemse P; Kluytmans JA
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3189-91. PubMed ID: 16940127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopeptide resistance amongst Staphylococcus spp.
    van den Braak N; van Belkum A; te Witt R; Verbrugh HA; Endtz HP
    J Antimicrob Chemother; 1998 Nov; 42(5):673-5. PubMed ID: 9848458
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycopeptide-resistant Staphylococcus aureus.
    Johnson AP; Woodford N
    J Antimicrob Chemother; 2002 Nov; 50(5):621-3. PubMed ID: 12407116
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
    Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycopeptide resistance in Staphylococcus aureus.
    Dancer SJ
    J Antimicrob Chemother; 2003 May; 51(5):1309-11. PubMed ID: 12668575
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
    Gemmell CG
    J Infect Chemother; 2004 Apr; 10(2):69-75. PubMed ID: 15160298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK.
    Kirby A; Graham R; Williams NJ; Wootton M; Broughton CM; Alanazi M; Anson J; Neal TJ; Parry CM
    J Antimicrob Chemother; 2010 Apr; 65(4):721-4. PubMed ID: 20124288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could antibiotic-resistant pathogens be cross-resistant to hard-surface disinfectants?
    Haines KA; Klein DA; McDonnell G; Pretzer D
    Am J Infect Control; 1997 Oct; 25(5):439-41. PubMed ID: 9343632
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.
    Maki H; McCallum N; Bischoff M; Wada A; Berger-Bächi B
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1953-9. PubMed ID: 15155184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2013 Apr; 41(4):397-8. PubMed ID: 23374976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.